Logo image of ALGS

ALIGOS THERAPEUTICS INC (ALGS) Stock Price, Quote, News and Overview

NASDAQ:ALGS - Nasdaq - US01626L2043 - Common Stock - Currency: USD

5.93  -0.13 (-2.15%)

ALGS Quote, Performance and Key Statistics

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (5/21/2025, 1:21:12 PM)

5.93

-0.13 (-2.15%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High46.8
52 Week Low3.76
Market Cap36.23M
Shares6.11M
Float4.70M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-04 2025-08-04/amc
IPO10-16 2020-10-16


ALGS short term performance overview.The bars show the price performance of ALGS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40 -60

ALGS long term performance overview.The bars show the price performance of ALGS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALGS is 5.93 USD. In the past month the price increased by 17.9%. In the past year, price decreased by -58.21%.

ALIGOS THERAPEUTICS INC / ALGS Daily stock chart

ALGS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.71 321.82B
AMGN AMGEN INC 13.06 145.72B
GILD GILEAD SCIENCES INC 13.99 134.81B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.87B
REGN REGENERON PHARMACEUTICALS 13.56 64.89B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.92B
ARGX ARGENX SE - ADR 99.93 35.82B
ONC BEIGENE LTD-ADR 5.88 25.46B
BNTX BIONTECH SE-ADR N/A 23.63B
NTRA NATERA INC N/A 20.69B
SMMT SUMMIT THERAPEUTICS INC N/A 19.55B
BIIB BIOGEN INC 8.2 19.00B

About ALGS

Company Profile

ALGS logo image Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Company Info

ALIGOS THERAPEUTICS INC

One Corporate Dr., 2Nd Floor, 2nd Floor

South San Francisco CALIFORNIA 94080 US

CEO: Lawrence M. Blatt

Employees: 68

ALGS Company Website

ALGS Investor Relations

Phone: 18004666059

ALIGOS THERAPEUTICS INC / ALGS FAQ

What is the stock price of ALIGOS THERAPEUTICS INC today?

The current stock price of ALGS is 5.93 USD. The price decreased by -2.15% in the last trading session.


What is the ticker symbol for ALIGOS THERAPEUTICS INC stock?

The exchange symbol of ALIGOS THERAPEUTICS INC is ALGS and it is listed on the Nasdaq exchange.


On which exchange is ALGS stock listed?

ALGS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALIGOS THERAPEUTICS INC stock?

9 analysts have analysed ALGS and the average price target is 103.7 USD. This implies a price increase of 1648.74% is expected in the next year compared to the current price of 5.93. Check the ALIGOS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALIGOS THERAPEUTICS INC worth?

ALIGOS THERAPEUTICS INC (ALGS) has a market capitalization of 36.23M USD. This makes ALGS a Nano Cap stock.


How many employees does ALIGOS THERAPEUTICS INC have?

ALIGOS THERAPEUTICS INC (ALGS) currently has 68 employees.


What are the support and resistance levels for ALIGOS THERAPEUTICS INC (ALGS) stock?

ALIGOS THERAPEUTICS INC (ALGS) has a support level at 4.54 and a resistance level at 6.07. Check the full technical report for a detailed analysis of ALGS support and resistance levels.


Is ALIGOS THERAPEUTICS INC (ALGS) expected to grow?

The Revenue of ALIGOS THERAPEUTICS INC (ALGS) is expected to decline by -42.46% in the next year. Check the estimates tab for more information on the ALGS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ALIGOS THERAPEUTICS INC (ALGS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALIGOS THERAPEUTICS INC (ALGS) stock pay dividends?

ALGS does not pay a dividend.


When does ALIGOS THERAPEUTICS INC (ALGS) report earnings?

ALIGOS THERAPEUTICS INC (ALGS) will report earnings on 2025-08-04, after the market close.


What is the Price/Earnings (PE) ratio of ALIGOS THERAPEUTICS INC (ALGS)?

ALIGOS THERAPEUTICS INC (ALGS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.78).


What is the Short Interest ratio of ALIGOS THERAPEUTICS INC (ALGS) stock?

The outstanding short interest for ALIGOS THERAPEUTICS INC (ALGS) is 17.78% of its float. Check the ownership tab for more information on the ALGS short interest.


ALGS Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ALGS. When comparing the yearly performance of all stocks, ALGS is a bad performer in the overall market: 97.37% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALGS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ALGS. Both the profitability and financial health of ALGS have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALGS Financial Highlights

Over the last trailing twelve months ALGS reported a non-GAAP Earnings per Share(EPS) of -7.78. The EPS increased by 75.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -187.19%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%61.64%
Sales Q2Q%-68.46%
EPS 1Y (TTM)75.69%
Revenue 1Y (TTM)-74.6%

ALGS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to ALGS. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of 11.33% and a revenue growth -42.46% for ALGS


Ownership
Inst Owners46.76%
Ins Owners3.32%
Short Float %17.78%
Short Ratio5.04
Analysts
Analysts84.44
Price Target103.7 (1648.74%)
EPS Next Y11.33%
Revenue Next Year-42.46%